SecBot SecBot
6-K ·Filed Sep 3, 2026

HCM

HUTCHMED (China) Ltd
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001648257-26-000057
Notable filing: 6-K
Actionable Insight ▲ Bullish

The $110M upfront provides immediate cash runway and validates HUTCHMED's ATTC platform. Monitor the Phase I start in H2 2026 and any early clinical data readouts. The GSK partnership significantly de-risks development costs and adds a major pharma partner, which could drive re-rating. Watch for potential antitrust clearance as a near-term catalyst.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$14.11
T+0 close · Sep 3, 2026 · via day close
Latest settled
+0.64%
T+20 · $14.20 · next T+60 in 13d
Vs SPY
+1.83%
α at T+20
Latest observation
+6.04%
T+51 · FF3 residual α
  1. T+0 · Sep 3 $14.11entry
  2. T+1 · 2mo ago −0.14%α +0.24% · $14.09
  3. T+5 · 2mo ago −9.14%α −7.99% · $12.82
  4. T+20 · 7w ago +0.64%α +1.83% · $14.20
  5. T+51 · todayOpen
  6. T+60 · in 13d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HUTCHMED announced an exclusive worldwide licensing agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC) for colorectal, pancreatic, and lung cancers. The deal includes a $110 million upfront payment and up to $1.295 billion in total milestones plus tiered royalties, with HUTCHMED retaining rights in Greater China. This is a major non-dilutive validation of HUTCHMED's ATTC platform and provides significant near-term cash, though the asset is still pre-clinical with Phase I starting H2 2026.

Key Facts

  • HUTCHMED licensed HMPL-A830 (KRAS-EGFR ATTC) to GSK for ex-China rights.
  • Upfront payment of $110 million; total potential milestones up to $1.295 billion plus tiered royalties.
  • HUTCHMED retains full rights in Mainland China, Hong Kong, Macau, and Taiwan.
  • GSK gets right of first negotiation on one earlier-stage ATTC candidate.
  • Phase I clinical trial expected to start H2 2026 (NCT07718581).
  • BofA Securities acted as exclusive financial advisor to HUTCHMED.

Financial Impact

$110 million upfront + up to $1.185 billion in milestones + tiered royalties on net sales

cashrevenueR&D expense

Risk Factors

  • Deal subject to customary closing conditions including antitrust regulatory reviews.
  • HMPL-A830 is pre-clinical; Phase I has not yet started and clinical data may not replicate preclinical results.
  • Milestone payments are contingent on development and regulatory success, which is uncertain.
  • GSK has a right of first negotiation on one earlier-stage ATTC candidate, potentially limiting future partnering optionality.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001648257-26-000057
Document: hcm-20260903x6k.htm0001648257-26-000057
Document: 0001648257-26-000057-index-headers.html0001648257-26-000057
Document: 0001648257-26-000057-index.html0001648257-26-000057
Document: 0001648257-26-000057.txt0001648257-26-000057

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 3, 2026